E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：41
|
作者：
Claudiani, Simone [1 ]
Apperley, Jane F. [1 ]
Gale, Robert Peter [1 ]
Clark, Richard [2 ]
Szydlo, Richard [1 ]
Deplano, Simona [1 ]
Palanicawandar, Renuka [1 ]
Khorashad, Jamshid [1 ]
Foroni, Letizia [1 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;
D O I：
10.3324/haematol.2017.168740
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E297 / E299
页数：3
相关论文
共 50 条
  • [31] No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
    Pfirrmann, Markus
    Evtimova, Dobromira
    Saussele, Susanne
    Castagnetti, Fausto
    Cervantes, Francisco
    Janssen, Jeroen
    Hoffmann, Verena S.
    Gugliotta, Gabriele
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Hasford, Joerg
    Baccarani, Michele
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (05) : 843 - 850
  • [32] No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
    Markus Pfirrmann
    Dobromira Evtimova
    Susanne Saussele
    Fausto Castagnetti
    Francisco Cervantes
    Jeroen Janssen
    Verena S. Hoffmann
    Gabriele Gugliotta
    Rüdiger Hehlmann
    Andreas Hochhaus
    Joerg Hasford
    Michele Baccarani
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 843 - 850
  • [33] Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
    Hanfstein, Benjamin
    Lauseker, Michael
    Hehlmann, Ruediger
    Saussele, Susanne
    Erben, Philipp
    Dietz, Christian
    Fabarius, Alice
    Proetel, Ulrike
    Schnittger, Susanne
    Haferlach, Claudia
    Krause, Stefan W.
    Schubert, Joerg
    Einsele, Hermann
    Haenel, Mathias
    Dengler, Jolanta
    Falge, Christiane
    Kanz, Lothar
    Neubauer, Andreas
    Kneba, Michael
    Stegelmann, Frank
    Pfreundschuh, Michael
    Waller, Cornelius F.
    Spiekermann, Karsten
    Baerlocher, Gabriela M.
    Pfirrmann, Markus
    Hasford, Joerg
    Hofmann, Wolf-Karsten
    Hochhaus, Andreas
    Mueller, Martin C.
    HAEMATOLOGICA, 2014, 99 (09) : 1441 - 1447
  • [34] Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation
    Ernst, Philipp
    Rinke, Jenny
    Franke, Georg-Nikolaus
    Dicker, Frank
    Haferlach, Torsten
    Ernst, Thomas
    Hochhaus, Andreas
    LEUKEMIA, 2024, 38 (09) : 2037 - 2040
  • [35] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1 (vol 15, 100233, 2021)
    Takeuchi, A.
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [36] HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Ureshino, Hiroshi
    Shindo, Takero
    Tanaka, Hidenori
    Saji, Hiroh
    Kimura, Shinya
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (01) : 142 - 149
  • [37] Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients
    Kockerols, Camille
    Valk, Peter J. M.
    Janssen, Jeroen J. W. M.
    Hogenbirk, Pauline
    Cornelissen, Jan J.
    Saussele, Susanne
    Spiess, Birgit
    Perusini, Maria Agustina
    Kim, Dennis
    Westerweel, Peter E.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (05) : 606 - 613
  • [38] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
    Lucas, Claire M.
    Harris, Robert J.
    Giannoudis, Athina
    Davies, Andrea
    Knight, Katy
    Watmough, Sarah J.
    Wang, Lihui
    Clark, Richard E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1362 - 1367
  • [39] Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations
    Ai, Jing
    Tiu, Ramon V.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (04) : 107 - 120
  • [40] Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission
    Stuckey, Ruth
    Lopez Rodriguez, Juan Francisco
    Gomez-Casares, Maria Teresa
    CURRENT ONCOLOGY REPORTS, 2022, 24 (04) : 415 - 426
12345